Featured
What doctors really want Reps to talk about
More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...
Leadership & People
Country boss adds new leadership hat
AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment
Pipeline & Intellectual Property
Pharma signs its biggest ever milestones deal
Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs
Patients
Omico names genomic profiling partners
Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program
Industry & Companies
One webpage, 11 Code Breaches
The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee which described the company's missteps as an embarrassment to the industry
Regulatory & Reimbursement
11 drugs join TGA review list
An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year
Government & Policy
Blue wave to break against MFN
The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines
Pipeline & Intellectual Property
Drug fails four months after $2.2B upfront buy
Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July
Regulatory & Reimbursement
What drugs are on MS patients' Wish List?
While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded
Pipeline & Intellectual Property
Can pharma sustain the blockbuster boom?
The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs
Industry & Companies
Who's opening its doors in the US?
Just months after undergoing a major rebrand, this Australian biotech is embarking on its next phase of growth, with plans to establish a US subsidiary
Regulatory & Reimbursement
Pharmac says no to weight loss funding
The decision came despite a high-priority recommendation from its Advisory Group with the current fiscal environment and constraints of the public health system to blame
Featured
Aussie race to market kicks off for obesity pills
The first oral GLP-1 drug has been approved for use in Australia for weight loss and will likely hit the private market this year, with a rival hot on its heels
Jobs
Featured
Aussies tapped for regional roles
In the latest round of job moves, industry leaders move up alongside long-timers changing companies - one after almost 30 years working at the same pharma
Industry & Companies
AZ shuffles jobs to prep huge pipeline
The UK pharma giant has announced a "reshaping" programme which will see jobs lost in some areas but gained in others
Awards
Meet the Best Drugs of 2026
A drug currently seeking to unlock broader government subsidy in Australia was crowned one of the best products of 2026 at the Prix Galien USA awards
Regulatory & Reimbursement
Aussie study applauds new-gen Novartis drug
South Australian researchers have described one of Novartis' fastest-growing brands as "a huge step forward" in frontline treatment options
Pipeline & Intellectual Property
Qld radiopharma defends manufacturing process
AdvanCell has challenged two patent application by a Norwegian company that cover the production of the radioisotope used in its flagship product
Pipeline & Intellectual Property
Aussies find new combo to tackle deadly cancer
After this drug wowed ESMO last month Australian researchers have discovered another combo that could disrupt treatment for small cell lung cancer
Leadership & People
Ex-Novartis GM snapped up for global role
So that's where he's gone... Well-known Aussie pharma exec has been tapped for a global position, joining a new company at a time of significant growth
Regulation & Legal
Federal Court slaps company with $6.5M fine
TGA wins its case against a company which unlawfully advertised prescription-only medicines, which the judge described as a "deliberate commercial strategy"
Government & Policy
AbbVie pitches a world-class PBS
As concerns grow over Australia’s lagging access to medicines, AbbVie has released a report exposing just how far the country has fallen behind and who is paying the price
Regulatory & Reimbursement
Who nabbed half the November PBS listings?
Eight drugs won reimbursement over the weekend, with half of the medicines belonging to one pharma
Regulatory & Reimbursement
Three pharmas hit with first rival
The TGA has approved the first copycats of long-standing drugs sponsored by Bayer, Link Medical Products, and Novo in Australia
Regulatory & Reimbursement
Aussies continue FDA winning streak
Melbourne-based pharma notches another win in the US with the granting of an Orphan Drug designation, marking an important commercial milestone
Government & Policy
Guild turns up heat on PBS prices
New poll puts pressure on Govt to freeze the PBS co-pay at $25 amid a cost-of-living crisis, just a couple of months out from a scheduled price hike
Industry & Companies
Out-of-pocket obesity drugs drives Lilly profits
Company rockets past analyst predictions thanks to a booming private market for its weight loss medications, smashing forecasts for the third quarter running
Latest
Health leaders of tomorrow start here
AbbVie helps inspire the next generation of changemakers by backing the Future Health Leaders Program alongside Research Australia and the CSIRO
Featured
Is the era of rising drug prices over?
The prices of new drugs at launch rose by over a third from 2022 to 2025, but the trend came to an abrupt end in the last year. Is this the start of a new era?
- Patients Patients pick favourite pharma
- Pipeline & Intellectual Property Six-way legal stoush over $47.5M market
- Government & Policy Biologics finally move to first line in paediatric Crohn's
- Industry & Companies MA lands its 50th member
- Leadership & People Ex-Aussie GM lands top new role
- Industry & Companies Top pharma employers as voted by staff
- Pipeline & Intellectual Property CEO stands by takeover despite US$1.9B hit
- Pipeline & Intellectual Property Astellas bets $1.89B on Aussie drug
- Government & Policy Dept boasts faster medicines access
- Pipeline & Intellectual Property Cancer drug's 'unprecedented' trial results